Absci (NASDAQ:ABSI) Releases Earnings Results, Misses Expectations By $0.04 EPS

Absci (NASDAQ:ABSI) released its earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04), FiscalAI reports. Absci had a negative net margin of 4,071.19% and a negative return on equity of 60.19%. The business had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $1.38 million.

Here are the key takeaways from Absci’s conference call:

• ABS-201 has dosed the first three SAD cohorts in the phase I/IIa HEADLINE trial; management reports favorable emerging safety and PK data and is on track to dose SAD Cohort 4 and the first MAD cohort.
• Management laid out a near-term milestone timeline — primary safety/tolerability and PK data in H1 2026, a 13-week interim proof-of-concept in AGA in H2 2026, full 26-week POC in early 2027, and planned initiation of a phase II endometriosis trial in Q4 2026 (using HEADLINE safety/PK data).
• Company-backed market research and KOL feedback indicate strong patient interest in the ABS-201 target product profile (durable effect with ~2–3 subcutaneous doses over ~6 months); Absci estimates a U.S. AGA addressable population of ~15–18M and suggests the AGA TAM could exceed $25 billion annually if assumptions hold.
• Financials and strategy — Absci reported $144.3M in cash, cash equivalents, and marketable securities as of 12/31/25 (stated runway into H1 2028) and plans to prioritize ABS-201 while pursuing partnerships or transactions for other programs (ABS-101/301/501) to generate non-dilutive cash.

Absci Trading Up 2.7%

NASDAQ ABSI opened at $3.01 on Wednesday. Absci has a 1-year low of $2.01 and a 1-year high of $5.23. The firm’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.21. The company has a market capitalization of $452.61 million, a PE ratio of -3.34 and a beta of 2.12.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a research report on Wednesday, January 21st. HC Wainwright raised their price objective on Absci from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Absci in a research note on Wednesday, March 18th. Finally, Morgan Stanley downgraded Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 target price on the stock. in a report on Thursday, January 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.08.

Trending Headlines about Absci

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Clinical progress: Absci reported successful dosing of the first three SAD cohorts in the ABS-201 HEADLINE trial with favorable emerging safety data — a tangible development that de‑risks the program and supports long‑term value for a drug‑discovery company. Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Management narrative: Earnings‑call coverage highlights strategic advances and commentary on business priorities and cash/resource allocation that investors view as constructive for execution and partner interest. Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience
• Neutral Sentiment: Full transcript available: The complete earnings‑call transcript provides detail on milestones, timelines and partnering discussions — useful for active investors but not an immediate catalyst by itself. Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short‑interest data flagged as a “significant increase” in multiple reports but the underlying figures show zeros/NaN — the data appears unreliable and should be treated cautiously; no clear short squeeze/coverage signal. (Multiple short‑interest entries dated March 23–24.)
• Negative Sentiment: Earnings and revenue miss: ABSI reported Q4 EPS of ($0.20) vs. consensus (~($0.16)) and revenue of $0.65M vs. ~$1.38M — the miss and continued losses keep near‑term financials pressured and justify analyst caution. Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates

Insiders Place Their Bets

In other Absci news, CEO Sean Mcclain sold 26,761 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $2.99, for a total value of $80,015.39. Following the transaction, the chief executive officer directly owned 8,334,567 shares of the company’s stock, valued at $24,920,355.33. This represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andreas Busch purchased 100,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were purchased at an average cost of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider directly owned 421,446 shares in the company, valued at approximately $965,111.34. This represents a 31.11% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 10.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Absci

Hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC acquired a new stake in Absci in the fourth quarter valued at approximately $50,000. Xponance LLC acquired a new position in shares of Absci during the 4th quarter worth $37,000. CIBC Bancorp USA Inc. acquired a new position in shares of Absci during the 3rd quarter worth $43,000. Jain Global LLC bought a new position in shares of Absci during the 3rd quarter valued at $104,000. Finally, Brooklyn Investment Group raised its holdings in shares of Absci by 13,498.1% during the 3rd quarter. Brooklyn Investment Group now owns 21,485 shares of the company’s stock valued at $65,000 after purchasing an additional 21,327 shares in the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.